{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T14:30:37Z","timestamp":1794061837870,"version":"4.8.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T00:00:00Z","timestamp":1605830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The nonsteroidal mineralocorticoid receptor (MR) blocker esaxerenone has demonstrated good antihypertensive activity in a variety of patients, including those with uncomplicated grade I\u2013III hypertension, hypertension with moderate renal dysfunction, hypertension with type 2 diabetes mellitus with albuminuria, and hypertension associated with primary aldosteronism. Hyperkalemia has long been recognized as a potential side effect occurring during treatment with MR blockers, but there is a lack of understanding and guidance about the appropriate management of hyperkalemia during antihypertensive therapy with MR blockers, especially in regard to the newer agent esaxerenone. In this article, we first highlight risk factors for hyperkalemia, including advanced chronic kidney disease, diabetes mellitus, cardiovascular disease, age, and use of renin-angiotensin-aldosterone system inhibitors. Next, we examine approaches to prevention and management, including potassium monitoring, diet, and the use of appropriate therapeutic techniques. Finally, we summarize the currently available data for esaxerenone and hyperkalemia. Proper management of serum potassium is required to ensure safe clinical use of MR blockers, including awareness of at-risk patient groups, choosing appropriate dosages for therapy initiation and dosage titration, and monitoring of serum potassium during therapy. It is critical that physicians take such factors into consideration to optimize MR blocker therapy in patients with hypertension.<\/jats:p>","DOI":"10.1038\/s41440-020-00569-y","type":"journal-article","created":{"date-parts":[[2020,11,20]],"date-time":"2020-11-20T02:03:32Z","timestamp":1605837812000},"page":"371-385","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Management of hyperkalemia during treatment with mineralocorticoid receptor blockers: findings from esaxerenone"],"prefix":"10.1038","volume":"44","author":[{"given":"Hiromi","family":"Rakugi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Yamakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotaro","family":"Sugimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,11,20]]},"reference":[{"key":"569_CR1","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.HYP.0000259805.18468.8c","volume":"49","author":"N Chapman","year":"2007","unstructured":"Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension. 2007;49:839\u201345.","journal-title":"Hypertension"},{"key":"569_CR2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N. Engl J Med. 2011;364:11\u201321.","journal-title":"N. Engl J Med"},{"key":"569_CR3","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1111\/jch.12860","volume":"18","author":"K Eguchi","year":"2016","unstructured":"Eguchi K, Kabutoya T, Hoshide S, Ishikawa S, Kario K. Add-on use of eplerenone is effective for lowering home and ambulatory blood pressure in drug-resistant hypertension. J Clin Hypertens. 2016;18:1250\u20137.","journal-title":"J Clin Hypertens"},{"key":"569_CR4","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0895-7061(03)01032-X","volume":"16","author":"MK Nishizaka","year":"2003","unstructured":"Nishizaka MK, Zaman MA, Calhoun DA. Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens. 2003;16:925\u201330.","journal-title":"Am J Hypertens"},{"key":"569_CR5","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309\u201321.","journal-title":"N Engl J Med"},{"key":"569_CR6","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"569_CR7","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0895-7061(02)02957-6","volume":"15","author":"MH Weinberger","year":"2002","unstructured":"Weinberger MH, Roniker B, Krause SL, Weiss RJ. Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension. Am J Hypertens. 2002;15:709\u201316.","journal-title":"Am J Hypertens"},{"key":"569_CR8","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1016\/S0140-6736(15)00257-3","volume":"386","author":"B Williams","year":"2015","unstructured":"Williams B, MacDonald TM, Morant S, Webb DJ, Sever P, McInnes G, et al. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet. 2015;386:2059\u201368.","journal-title":"Lancet"},{"key":"569_CR9","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"GL Bakris","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC, Cooper ME, Gansevoort RT, Haller H, et al. Effect of finerenone on albuminuria in patients with diabetic nephropathy: a randomized clinical trial. JAMA. 2015;314:884\u201394.","journal-title":"JAMA"},{"key":"569_CR10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1136\/heartjnl-2018-313599","volume":"105","author":"JJ Noubiap","year":"2019","unstructured":"Noubiap JJ, Nansseu JR, Nyaga UF, Sime PS, Francis I, Bigna JJ. Global prevalence of resistant hypertension: a meta-analysis of data from 3.2 million patients. Heart. 2019;105:98\u2013105.","journal-title":"Heart"},{"key":"569_CR11","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1097\/HJH.0b013e3283599b6a","volume":"31","author":"G Colussi","year":"2013","unstructured":"Colussi G, Catena C, Sechi LA. Spironolactone, eplerenone and the new aldosterone blockers in endocrine and primary hypertension. J Hypertens. 2013;31:3\u201315.","journal-title":"J Hypertens"},{"key":"569_CR12","unstructured":"Pfizer. Aldactone\u00ae spironolactone tablets, USP. Prescribing information. New York: Pfizer; 2008. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/012151s062lbl.pdf."},{"key":"569_CR13","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/hr.2012.182","volume":"36","author":"A Sato","year":"2013","unstructured":"Sato A. Mineralocorticoid receptor antagonists: their use and differentiation in Japan. Hypertens Res. 2013;36:185\u201390.","journal-title":"Hypertens Res"},{"key":"569_CR14","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ijcard.2014.09.091","volume":"177","author":"F Pelliccia","year":"2014","unstructured":"Pelliccia F, Patti G, Rosano G, Greco C, Gaudio C. Efficacy and safety of eplerenone in the management of mild to moderate arterial hypertension: systematic review and meta-analysis. Int J Cardiol. 2014;177:219\u201328.","journal-title":"Int J Cardiol"},{"key":"569_CR15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/HJH.0000000000000762","volume":"34","author":"GC Roush","year":"2016","unstructured":"Roush GC, Ernst ME, Kostis JB, Yeasmin S, Sica DA. Dose doubling, relative potency, and dose equivalence of potassium-sparing diuretics affecting blood pressure and serum potassium: systematic review and meta-analyses. J Hypertens. 2016;34:11\u20139.","journal-title":"J Hypertens"},{"key":"569_CR16","unstructured":"Pfizer. INSPRA\u00ae (eplerenone) tablets, for oral use. Prescribing information. New York: Pfizer; 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/021437s015lbl.pdf."},{"key":"569_CR17","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.ejphar.2015.11.028","volume":"769","author":"K Arai","year":"2015","unstructured":"Arai K, Tsuruoka H, Homma T. CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats. Eur J Pharm. 2015;769:266\u201373.","journal-title":"Eur J Pharm"},{"key":"569_CR18","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/bcp.13616","volume":"84","author":"M Kato","year":"2018","unstructured":"Kato M, Furuie H, Shimizu T, Miyazaki A, Kobayashi F, Ishizuka H. Single- and multiple-dose escalation study to assess pharmacokinetics, pharmacodynamics and safety of oral esaxerenone in healthy Japanese subjects. Br J Clin Pharm. 2018;84:1821\u20139.","journal-title":"Br J Clin Pharm"},{"key":"569_CR19","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"P Kolkhof","year":"2017","unstructured":"Kolkhof P, Barfacker L. 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development. J Endocrinol. 2017;234:T125\u201340.","journal-title":"J Endocrinol"},{"key":"569_CR20","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s11906-020-1023-y","volume":"22","author":"D Sueta","year":"2020","unstructured":"Sueta D, Yamamoto E, Tsujita K. Mineralocorticoid receptor blockers: novel selective nonsteroidal mineralocorticoid receptor antagonists. Curr Hypertens Rep. 2020;22:21.","journal-title":"Curr Hypertens Rep"},{"key":"569_CR21","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/cts.12705","volume":"13","author":"A Whittaker","year":"2020","unstructured":"Whittaker A, Kragh AM, Hartleib-Geschwindner J, Albayaty M, Backlund A, Greasley PJ, et al. Safety, tolerability, and pharmacokinetics of the mineralocorticoid receptor modulator AZD9977 in healthy men: a phase I multiple ascending dose study. Clin Transl Sci. 2020;13:275\u201383.","journal-title":"Clin Transl Sci"},{"key":"569_CR22","unstructured":"Daiichi-Sankyo. Minnebro\u00ae (esaxerenone) tablets 1.25\u2009mg, 2.5\u2009mg, 5\u2009mg. Package insert. Tokyo: Daiichi-Sankyo; 2020. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00067892.pdf."},{"key":"569_CR23","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1007\/s40265-019-01073-5","volume":"79","author":"S Duggan","year":"2019","unstructured":"Duggan S. Esaxerenone: first global approval. Drugs. 2019;79:477\u201381.","journal-title":"Drugs"},{"key":"569_CR24","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejphar.2015.06.015","volume":"761","author":"K Arai","year":"2015","unstructured":"Arai K, Homma T, Morikawa Y, Ubukata N, Tsuruoka H, Aoki K, et al. Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist. Eur J Pharm. 2015;761:226\u201334.","journal-title":"Eur J Pharm"},{"key":"569_CR25","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/HYPERTENSIONAHA.119.13569","volume":"75","author":"S Ito","year":"2020","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yoshimura M, Yamakawa S. Double-blind randomized phase 3 study comparing esaxerenone (CS-3150) and eplerenone in patients with essential hypertension (ESAX-HTN study). Hypertension. 2020;75:51\u20138.","journal-title":"Hypertension"},{"key":"569_CR26","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1038\/s41440-019-0270-2","volume":"42","author":"H Itoh","year":"2019","unstructured":"Itoh H, Ito S, Rakugi H, Okuda Y, Nishioka S. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertens Res. 2019;42:1572\u201381.","journal-title":"Hypertens Res"},{"key":"569_CR27","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/s41440-019-0314-7","volume":"42","author":"H Rakugi","year":"2019","unstructured":"Rakugi H, Ito S, Itoh H, Okuda Y, Yamakawa S. Long-term phase 3 study of esaxerenone as mono or combination therapy with other antihypertensive drugs in patients with essential hypertension. Hypertens Res. 2019;42:1932\u201341.","journal-title":"Hypertens Res"},{"key":"569_CR28","first-page":"755","volume":"40","author":"H Rakugi","year":"2020","unstructured":"Rakugi H, Ito S, Ito H, Okuda Y, Iijima S. The efficacy and safety of esaxerenone for patients with grade III hypertension. Prog Med. 2020;40:755\u201360.","journal-title":"Prog Med"},{"key":"569_CR29","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","volume":"200","author":"M Lainscak","year":"2015","unstructured":"Lainscak M, Pelliccia F, Rosano G, Vitale C, Schiariti M, Greco C, et al. Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone. Int J Cardiol. 2015;200:25\u20139.","journal-title":"Int J Cardiol"},{"key":"569_CR30","doi-asserted-by":"crossref","first-page":"235","DOI":"10.14797\/mdcj-11-4-235","volume":"11","author":"DA Sica","year":"2015","unstructured":"Sica DA. Mineralocorticoid receptor antagonists for treatment of hypertension and heart failure. Methodist Debakey Cardiovasc J. 2015;11:235\u20139.","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"569_CR31","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1056\/NEJMoa040135","volume":"351","author":"DN Juurlink","year":"2004","unstructured":"Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N. Engl J Med. 2004;351:543\u201351.","journal-title":"N. Engl J Med"},{"key":"569_CR32","unstructured":"Japan Pharmaceuticals and Medical Devices Agency. Pharmaceutical interview: esaxerenone 1.25\u2009mg, 2.5\u2009mg, 5\u2009mg. Tokyo: Japan Pharmaceuticals and Medical Devices Agency; 2020. http:\/\/www.info.pmda.go.jp\/go\/interview\/1\/430574_2149049F1027_1_MN4_1F."},{"key":"569_CR33","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.resuscitation.2010.08.015","volume":"81","author":"J Soar","year":"2010","unstructured":"Soar J, Perkins GD, Abbas G, Alfonzo A, Barelli A, Bierens JJ, et al. European Resuscitation Council Guidelines for Resuscitation 2010 Section 8. Cardiac arrest in special circumstances: electrolyte abnormalities, poisoning, drowning, accidental hypothermia, hyperthermia, asthma, anaphylaxis, cardiac surgery, trauma, pregnancy, electrocution. Resuscitation. 2010;81:1400\u201333.","journal-title":"Resuscitation"},{"key":"569_CR34","doi-asserted-by":"crossref","unstructured":"Guidelines 2000 for cardiopulmonary resuscitation and emergency cardiovascular care. Part 8: Advanced challenges in resuscitation: Section 1: Life-threatening electrolyte abnormalities. The American Heart Association in collaboration with the International Liaison Committee on Resuscitation. Circulation. 2000;102:I217\u201322.","DOI":"10.1161\/01.CIR.102.suppl_1.I-217"},{"key":"569_CR35","unstructured":"Japanese Ministry of Health, Labor and Welfare. The Serious Side Effects Comprehensive Measures Study Group. Classification criteria for the seriousness of adverse drug reactions of medical agents. No. 80. Japanese Ministry of Health, Labor and Welfare. 1992. https:\/\/www.mhlw.go.jp\/content\/11121000\/000529049.pdf."},{"key":"569_CR36","unstructured":"The Japanese Society of Nephrology. Evidence-based clinical practice guideline for CKD. Tokyo: The Japanese Society of Nephrology; 2018. https:\/\/cdn.jsn.or.jp\/data\/CKD2018.pdf."},{"key":"569_CR37","doi-asserted-by":"crossref","first-page":"324","DOI":"10.2215\/CJN.04611007","volume":"3","author":"BT Montague","year":"2008","unstructured":"Montague BT, Ouellette JR, Buller GK. Retrospective review of the frequency of ECG changes in hyperkalemia. Clin J Am Soc Nephrol. 2008;3:324\u201330.","journal-title":"Clin J Am Soc Nephrol"},{"key":"569_CR38","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jacc.2003.06.021","volume":"43","author":"JE Macdonald","year":"2004","unstructured":"Macdonald JE, Struthers AD. What is the optimal serum potassium level in cardiovascular patients? J Am Coll Cardiol. 2004;43:155\u201361.","journal-title":"J Am Coll Cardiol"},{"key":"569_CR39","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.kisu.2016.01.003","volume":"6","author":"VM Campese","year":"2016","unstructured":"Campese VM, Adenuga G. Electrophysiological and clinical consequences of hyperkalemia. Kidney Int Suppl (2011). 2016;6:16\u201319.","journal-title":"Kidney Int Suppl (2011)"},{"key":"569_CR40","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/bja\/70.2.226","volume":"70","author":"SJ Freeman","year":"1993","unstructured":"Freeman SJ, Fale AD. Muscular paralysis and ventilatory failure caused by hyperkalaemia. Br J Anaesth. 1993;70:226\u20137.","journal-title":"Br J Anaesth"},{"key":"569_CR41","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1001\/jama.2011.1967","volume":"307","author":"A Goyal","year":"2012","unstructured":"Goyal A, Spertus JA, Gosch K, Venkitachalam L, Jones PG, Van den Berghe G, et al. Serum potassium levels and mortality in acute myocardial infarction. JAMA. 2012;307:157\u201364.","journal-title":"JAMA"},{"key":"569_CR42","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1681\/ASN.2016121344","volume":"28","author":"JR Montford","year":"2017","unstructured":"Montford JR, Linas S. How dangerous Is hyperkalemia? J Am Soc Nephrol. 2017;28:3155\u201365.","journal-title":"J Am Soc Nephrol"},{"key":"569_CR43","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1152\/advan.00121.2016","volume":"40","author":"BF Palmer","year":"2016","unstructured":"Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis. Adv Physiol Educ. 2016;40:480\u201390.","journal-title":"Adv Physiol Educ"},{"key":"569_CR44","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1053\/j.ajkd.2019.03.427","volume":"74","author":"BF Palmer","year":"2019","unstructured":"Palmer BF, Clegg DJ. Physiology and pathophysiology of potassium homeostasis: core curriculum 2019. Am J Kidney Dis. 2019;74:682\u201395.","journal-title":"Am J Kidney Dis"},{"key":"569_CR45","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/mus.880080104","volume":"8","author":"G Comi","year":"1985","unstructured":"Comi G, Testa D, Cornelio F, Comola M, Canal N. Potassium depletion myopathy: a clinical and morphological study of six cases. Muscle Nerve. 1985;8:17\u201321.","journal-title":"Muscle Nerve"},{"key":"569_CR46","first-page":"46","volume":"21","author":"G Marti","year":"2014","unstructured":"Marti G, Schwarz C, Leichtle AB, Fiedler GM, Arampatzis S, Exadaktylos AK, et al. Etiology and symptoms of severe hypokalemia in emergency department patients. Eur J Emerg Med. 2014;21:46\u201351.","journal-title":"Eur J Emerg Med"},{"key":"569_CR47","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1159\/000116702","volume":"31","author":"S Shintani","year":"1991","unstructured":"Shintani S, Shiigai T, Tsukagoshi H. Marked hypokalemic rhabdomyolysis with myoglobinuria due to diuretic treatment. Eur Neurol. 1991;31:396\u20138.","journal-title":"Eur Neurol"},{"key":"569_CR48","first-page":"104","volume":"38","author":"ML Krogager","year":"2017","unstructured":"Krogager ML, Torp-Pedersen C, Mortensen RN, Kober L, Gislason G, Sogaard P, et al. Short-term mortality risk of serum potassium levels in hypertension: a retrospective analysis of nationwide registry data. Eur Heart J. 2017;38:104\u201312.","journal-title":"Eur Heart J"},{"key":"569_CR49","doi-asserted-by":"crossref","first-page":"90","DOI":"10.2215\/CJN.01730215","volume":"11","author":"J Luo","year":"2016","unstructured":"Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11:90\u2013100.","journal-title":"Clin J Am Soc Nephrol"},{"key":"569_CR50","volume":"16","author":"JN An","year":"2012","unstructured":"An JN, Lee JP, Jeon HJ, Kim DH, Oh YK, Kim YS, et al. Severe hyperkalemia requiring hospitalization: predictors of mortality. Crit Care. 2012;16:R225.","journal-title":"Crit Care"},{"key":"569_CR51","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ekir.2019.05.018","volume":"4","author":"N Kashihara","year":"2019","unstructured":"Kashihara N, Kohsaka S, Kanda E, Okami S, Yajima T. Hyperkalemia in real-world patients under continuous medical care in Japan. Kidney Int Rep. 2019;4:1248\u201360.","journal-title":"Kidney Int Rep"},{"key":"569_CR52","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1093\/eurheartj\/ehm091","volume":"28","author":"A Ahmed","year":"2007","unstructured":"Ahmed A, Zannad F, Love TE, Tallaj J, Gheorghiade M, Ekundayo OJ, et al. A propensity-matched study of the association of low serum potassium levels and mortality in chronic heart failure. Eur Heart J. 2007;28:1334\u201343.","journal-title":"Eur Heart J"},{"key":"569_CR53","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1161\/CIRCHEARTFAILURE.109.899526","volume":"3","author":"CB Bowling","year":"2010","unstructured":"Bowling CB, Pitt B, Ahmed MI, Aban IB, Sanders PW, Mujib M, et al. Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail. 2010;3:253\u201360.","journal-title":"Circ Heart Fail"},{"key":"569_CR54","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1093\/eurheartj\/ehx460","volume":"38","author":"M Aldahl","year":"2017","unstructured":"Aldahl M, Jensen AC, Davidsen L, Eriksen MA, Moller Hansen S, Nielsen BJ, et al. Associations of serum potassium levels with mortality in chronic heart failure patients. Eur Heart J. 2017;38:2890\u20136.","journal-title":"Eur Heart J"},{"key":"569_CR55","doi-asserted-by":"crossref","first-page":"5411","DOI":"10.1016\/j.ijcard.2013.08.048","volume":"168","author":"BP Krijthe","year":"2013","unstructured":"Krijthe BP, Heeringa J, Kors JA, Hofman A, Franco OH, Witteman JC, et al. Serum potassium levels and the risk of atrial fibrillation: the Rotterdam Study. Int J Cardiol. 2013;168:5411\u20135.","journal-title":"Int J Cardiol"},{"key":"569_CR56","first-page":"9","volume":"7","author":"P Widimsky","year":"2008","unstructured":"Widimsky P. Hypokalemia and the heart. E-J Cardiol Pr. 2008;7:9. https:\/\/www.escardio.org\/Journals\/E-Journal-of-Cardiology-Practice\/Volume-7\/Hypokalemia-and-the-heart.","journal-title":"E-J Cardiol Pr"},{"key":"569_CR57","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.amjcard.2012.01.367","volume":"109","author":"N Jain","year":"2012","unstructured":"Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, et al. Predictors of hyperkalemia and death in patients with cardiac and renal disease. Am J Cardiol. 2012;109:1510\u20133.","journal-title":"Am J Cardiol"},{"key":"569_CR58","first-page":"283","volume":"73","author":"JC Hollander-Rodriguez","year":"2006","unstructured":"Hollander-Rodriguez JC, Calvert JF Jr. Hyperkalemia. Am Fam Physician. 2006;73:283\u201390.","journal-title":"Am Fam Physician"},{"key":"569_CR59","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"C Ben Salem","year":"2014","unstructured":"Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug-induced hyperkalemia. Drug Saf. 2014;37:677\u201392.","journal-title":"Drug Saf"},{"key":"569_CR60","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1159\/000446268","volume":"2","author":"M Zacchia","year":"2016","unstructured":"Zacchia M, Abategiovanni ML, Stratigis S, Capasso G. Potassium: from physiology to clinical implications. Kidney Dis (Basel). 2016;2:72\u20139.","journal-title":"Kidney Dis (Basel)"},{"key":"569_CR61","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/j.1532-5415.2011.03818.x","volume":"60","author":"PE Drawz","year":"2012","unstructured":"Drawz PE, Babineau DC, Rahman M. Metabolic complications in elderly adults with chronic kidney disease. J Am Geriatr Soc. 2012;60:310\u20135.","journal-title":"J Am Geriatr Soc"},{"key":"569_CR62","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1001\/archinternmed.2009.284","volume":"169","author":"JM Weinberg","year":"2009","unstructured":"Weinberg JM, Appel LJ, Bakris G, Gassman JJ, Greene T, Kendrick CA, et al. Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy. Arch Intern Med. 2009;169:1587\u201394.","journal-title":"Arch Intern Med"},{"key":"569_CR63","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jash.2010.09.006","volume":"4","author":"J Heshka","year":"2010","unstructured":"Heshka J, Ruzicka M, Hiremath S, McCormick BB. Spironolactone for difficult to control hypertension in chronic kidney disease: an analysis of safety and efficacy. J Am Soc Hypertens. 2010;4:295\u2013301.","journal-title":"J Am Soc Hypertens"},{"key":"569_CR64","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s11606-009-1228-x","volume":"25","author":"MA Raebel","year":"2010","unstructured":"Raebel MA, Ross C, Xu S, Roblin DW, Cheetham C, Blanchette CM, et al. Diabetes and drug-associated hyperkalemia: effect of potassium monitoring. J Gen Intern Med. 2010;25:326\u201333.","journal-title":"J Gen Intern Med"},{"key":"569_CR65","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1159\/000479802","volume":"46","author":"AJ Collins","year":"2017","unstructured":"Collins AJ, Pitt B, Reaven N, Funk S, McGaughey K, Wilson D, et al. Association of serum potassium with all-cause mortality in patients with and without heart failure, chronic kidney disease, and\/or diabetes. Am J Nephrol. 2017;46:213\u201321.","journal-title":"Am J Nephrol"},{"key":"569_CR66","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1159\/000442393","volume":"42","author":"C Loutradis","year":"2015","unstructured":"Loutradis C, Tolika P, Skodra A, Avdelidou A, Sarafidis PA. Prevalence of hyperkalemia in diabetic and non-diabetic patients with chronic kidney disease: a nested case-control study. Am J Nephrol. 2015;42:351\u201360.","journal-title":"Am J Nephrol"},{"key":"569_CR67","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/dme.13687","volume":"35","author":"RW Thomsen","year":"2018","unstructured":"Thomsen RW, Nicolaisen SK, Adelborg K, Svensson E, Hasvold P, Palaka E, et al. Hyperkalaemia in people with diabetes: occurrence, risk factors and outcomes in a Danish population-based cohort study. Diabet Med. 2018;35:1051\u201360.","journal-title":"Diabet Med"},{"key":"569_CR68","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.hfc.2017.02.001","volume":"13","author":"K Dharmarajan","year":"2017","unstructured":"Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin. 2017;13:417\u201326.","journal-title":"Heart Fail Clin"},{"key":"569_CR69","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/nrneph.2016.113","volume":"12","author":"JC Schefold","year":"2016","unstructured":"Schefold JC, Filippatos G, Hasenfuss G, Anker SD, von Haehling S. Heart failure and kidney dysfunction: epidemiology, mechanisms and management. Nat Rev Nephrol. 2016;12:610\u201323.","journal-title":"Nat Rev Nephrol"},{"key":"569_CR70","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1159\/000493395","volume":"9","author":"L Di Lullo","year":"2019","unstructured":"Di Lullo L, Ronco C, Granata A, Paoletti E, Barbera V, Cozzolino M, et al. Chronic hyperkalemia in cardiorenal patients: risk factors, diagnosis, and new treatment options. Cardiorenal Med. 2019;9:8\u201321.","journal-title":"Cardiorenal Med"},{"key":"569_CR71","doi-asserted-by":"crossref","first-page":"A6","DOI":"10.1093\/eurheartj\/suy028","volume":"21","author":"J Tromp","year":"2019","unstructured":"Tromp J, van der Meer P. Hyperkalaemia: aetiology, epidemiology, and clinical significance. Eur Heart J Suppl. 2019;21:A6\u2013A11.","journal-title":"Eur Heart J Suppl"},{"key":"569_CR72","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2016.06.060","volume":"68","author":"CM Sarwar","year":"2016","unstructured":"Sarwar CM, Papadimitriou L, Pitt B, Pina I, Zannad F, Anker SD, et al. Hyperkalemia in heart failure. J Am Coll Cardiol. 2016;68:1575\u201389.","journal-title":"J Am Coll Cardiol"},{"key":"569_CR73","first-page":"315","volume":"14","author":"RH Schwinger","year":"1992","unstructured":"Schwinger RH, Erdmann E. Heart failure and electrolyte disturbances. Methods Find Exp Clin Pharm. 1992;14:315\u201325.","journal-title":"Methods Find Exp Clin Pharm"},{"key":"569_CR74","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/ejhf.226","volume":"17","author":"A Michel","year":"2015","unstructured":"Michel A, Martin-Perez M, Ruigomez A, Garcia Rodriguez LA. Risk factors for hyperkalaemia in a cohort of patients with newly diagnosed heart failure: a nested case-control study in UK general practice. Eur J Heart Fail. 2015;17:205\u201313.","journal-title":"Eur J Heart Fail"},{"key":"569_CR75","first-page":"141","volume":"55","author":"RW Berliner","year":"1961","unstructured":"Berliner RW. Renal mechanisms for potassium excretion. Harvey Lect. 1961;55:141\u201371.","journal-title":"Harvey Lect"},{"key":"569_CR76","first-page":"278","volume":"72","author":"S Adler","year":"1968","unstructured":"Adler S, Lindeman RD, Yiengst MJ, Beard E, Shock NW. Effect of acute acid loading on urinary acid excretion by the aging human kidney. J Lab Clin Med. 1968;72:278\u201389.","journal-title":"J Lab Clin Med"},{"key":"569_CR77","first-page":"346","volume":"4","author":"RP Shannon","year":"1984","unstructured":"Shannon RP, Minaker KL, Rowe JW. Aging and water balance in humans. Semin Nephrol. 1984;4:346\u201353.","journal-title":"Semin Nephrol"},{"key":"569_CR78","first-page":"S27","volume":"23","author":"R Kumar","year":"2017","unstructured":"Kumar R, Kanev L, Woods SD, Brenner M, Smith B. Managing hyperkalemia in high-risk patients in long-term care. Am J Manag Care. 2017;23:S27\u201336.","journal-title":"Am J Manag Care"},{"key":"569_CR79","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1161\/CIRCULATIONAHA.117.030576","volume":"137","author":"J Nunez","year":"2018","unstructured":"Nunez J, Bayes-Genis A, Zannad F, Rossignol P, Nunez E, Bodi V, et al. Long-term potassium monitoring and dynamics in heart failure and risk of mortality. Circulation. 2018;137:1320\u201330.","journal-title":"Circulation"},{"key":"569_CR80","doi-asserted-by":"crossref","first-page":"e156","DOI":"10.1111\/j.1755-5922.2010.00258.x","volume":"30","author":"MA Raebel","year":"2012","unstructured":"Raebel MA. Hyperkalemia associated with use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Cardiovasc Ther. 2012;30:e156\u201366.","journal-title":"Cardiovasc Ther"},{"key":"569_CR81","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/nrneph.2012.217","volume":"8","author":"SS Roscioni","year":"2012","unstructured":"Roscioni SS, de Zeeuw D, Bakker SJ, Lambers Heerspink HJ. Management of hyperkalaemia consequent to mineralocorticoid-receptor antagonist therapy. Nat Rev Nephrol. 2012;8:691\u20139.","journal-title":"Nat Rev Nephrol"},{"key":"569_CR82","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMc081065","volume":"359","author":"N Buchner","year":"2008","unstructured":"Buchner N, Banas B, Kramer BK. Telmisartan, ramipril, or both in patients at high risk of vascular events. N Engl J Med. 2008;359:426.","journal-title":"N Engl J Med"},{"key":"569_CR83","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s40256-018-00321-5","volume":"19","author":"Y Feng","year":"2019","unstructured":"Feng Y, Huang R, Kavanagh J, Li L, Zeng X, Li Y, et al. Efficacy and safety of dual blockade of the renin-angiotensin-aldosterone system in diabetic kidney disease: a meta-analysis. Am J Cardiovasc Drugs. 2019;19:259\u201386.","journal-title":"Am J Cardiovasc Drugs"},{"key":"569_CR84","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.ajkd.2006.04.077","volume":"48","author":"M MacKinnon","year":"2006","unstructured":"MacKinnon M, Shurraw S, Akbari A, Knoll GA, Jaffey J, Clark HD. Combination therapy with an angiotensin receptor blocker and an ACE inhibitor in proteinuric renal disease: a systematic review of the efficacy and safety data. Am J Kidney Dis. 2006;48:8\u201320.","journal-title":"Am J Kidney Dis"},{"key":"569_CR85","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1161\/HYPERTENSIONAHA.111.180554","volume":"59","author":"MH Alderman","year":"2012","unstructured":"Alderman MH, Piller LB, Ford CE, Probstfield JL, Oparil S, Cushman WC, et al. Clinical significance of incident hypokalemia and hyperkalemia in treated hypertensive patients in the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Hypertension. 2012;59:926\u201333.","journal-title":"Hypertension"},{"key":"569_CR86","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.amjcard.2004.01.007","volume":"93","author":"GH Williams","year":"2004","unstructured":"Williams GH, Burgess E, Kolloch RE, Ruilope LM, Niegowska J, Kipnes MS, et al. Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension. Am J Cardiol. 2004;93:990\u20136.","journal-title":"Am J Cardiol"},{"key":"569_CR87","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/sj.ki.5001580","volume":"70","author":"KJ Schjoedt","year":"2006","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Tarnow L, Rossing P, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536\u201342.","journal-title":"Kidney Int"},{"key":"569_CR88","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1097\/01.hjh.0000249708.44016.5c","volume":"24","author":"AH van den Meiracker","year":"2006","unstructured":"van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, et al. Spironolactone in type 2 diabetic nephropathy: efects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285\u201392.","journal-title":"J Hypertens"},{"key":"569_CR89","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00125-011-2325-z","volume":"54","author":"E Imai","year":"2011","unstructured":"Imai E, Chan JC, Ito S, Yamasaki T, Kobayashi F, Haneda M, et al. Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy: a multicentre, randomised, placebo-controlled study. Diabetologia. 2011;54:2978\u201386.","journal-title":"Diabetologia"},{"key":"569_CR90","first-page":"547","volume":"5","author":"SA Sadjadi","year":"2009","unstructured":"Sadjadi SA, McMillan JI, Jaipaul N, Blakely P, Hline SS. A comparative study of the prevalence of hyperkalemia with the use of angiotensin-converting enzyme inhibitors versus angiotensin receptor blockers. Ther Clin Risk Manag. 2009;5:547\u201352.","journal-title":"Ther Clin Risk Manag"},{"key":"569_CR91","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1177\/1479164117715854","volume":"14","author":"SL Zheng","year":"2017","unstructured":"Zheng SL, Roddick AJ, Ayis S. Effects of aliskiren on mortality, cardiovascular outcomes and adverse events in patients with diabetes and cardiovascular disease or risk: a systematic review and meta-analysis of 13,395 patients. Diab Vasc Dis Res. 2017;14:400\u20136.","journal-title":"Diab Vasc Dis Res"},{"key":"569_CR92","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"SOLVD Investigators, Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med"},{"key":"569_CR93","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772\u20136.","journal-title":"Lancet"},{"key":"569_CR94","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","volume":"20","author":"UF Mehdi","year":"2009","unstructured":"Mehdi UF, Adams-Huet B, Raskin P, Vega GL, Toto RD. Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol. 2009;20:2641\u201350.","journal-title":"J Am Soc Nephrol"},{"key":"569_CR95","doi-asserted-by":"crossref","first-page":"2116","DOI":"10.1038\/sj.ki.5001854","volume":"70","author":"S Bianchi","year":"2006","unstructured":"Bianchi S, Bigazzi R, Campese VM. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006;70:2116\u201323.","journal-title":"Kidney Int"},{"key":"569_CR96","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2215\/CJN.01040905","volume":"1","author":"A Chrysostomou","year":"2006","unstructured":"Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo-controlled study on the effect of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"569_CR97","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1291\/hypres.31.59","volume":"31","author":"Y Furumatsu","year":"2008","unstructured":"Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, et al. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker. Hypertens Res. 2008;31:59\u201367.","journal-title":"Hypertens Res"},{"key":"569_CR98","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.2337\/diacare.28.9.2106","volume":"28","author":"K Rossing","year":"2005","unstructured":"Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005;28:2106\u201312.","journal-title":"Diabetes Care"},{"key":"569_CR99","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1111\/j.1523-1755.2005.00756.x","volume":"68","author":"KJ Schjoedt","year":"2005","unstructured":"Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829\u201336.","journal-title":"Kidney Int"},{"key":"569_CR100","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1053\/j.ajkd.2008.02.297","volume":"52","author":"L Tylicki","year":"2008","unstructured":"Tylicki L, Rutkowski P, Renke M, Larczynski W, Aleksandrowicz E, Lysiak-Szydlowska W, et al. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial. Am J Kidney Dis. 2008;52:486\u201393.","journal-title":"Am J Kidney Dis"},{"key":"569_CR101","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1053\/j.ajkd.2005.03.007","volume":"46","author":"S Bianchi","year":"2005","unstructured":"Bianchi S, Bigazzi R, Campese VM. Antagonists of aldosterone and proteinuria in patients with CKD: an uncontrolled pilot study. Am J Kidney Dis. 2005;46:45\u201351.","journal-title":"Am J Kidney Dis"},{"key":"569_CR102","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1016\/j.transproceed.2010.08.024","volume":"42","author":"E Gonzalez Monte","year":"2010","unstructured":"Gonzalez Monte E, Andres A, Polanco N, Toribio MJ, Santana R, Gutierrez Martinez E, et al. Addition of spironolactone to dual blockade of renin angiotensin system dramatically reduces severe proteinuria in renal transplant patients: an uncontrolled pilot study at 6 months. Transpl Proc. 2010;42:2899\u2013901.","journal-title":"Transpl Proc"},{"key":"569_CR103","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","volume":"18","author":"A Sato","year":"2005","unstructured":"Sato A, Hayashi K, Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens. 2005;18:44\u20139.","journal-title":"Am J Hypertens"},{"key":"569_CR104","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3109\/08860220903216121","volume":"31","author":"E Sengul","year":"2009","unstructured":"Sengul E, Sahin T, Sevin E, Yilmaz A. Effect of spironolactone on urinary protein excretion in patients with chronic kidney disease. Ren Fail. 2009;31:928\u201332.","journal-title":"Ren Fail"},{"key":"569_CR105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.ijcard.2017.07.035","volume":"245","author":"E Nilsson","year":"2017","unstructured":"Nilsson E, Gasparini A, Arnlov J, Xu H, Henriksson KM, Coresh J, et al. Incidence and determinants of hyperkalemia and hypokalemia in a large healthcare system. Int J Cardiol. 2017;245:277\u201384.","journal-title":"Int J Cardiol"},{"key":"569_CR106","first-page":"S1","volume":"43","author":"Kidney Disease Outcomes Quality Initiative.","year":"2004","unstructured":"Kidney Disease Outcomes Quality Initiative. K\/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis. 2004;43:S1\u2013290.","journal-title":"Am J Kidney Dis"},{"key":"569_CR107","first-page":"e240","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Writing Committee Members, Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr., et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240\u2013327.","journal-title":"Circulation"},{"key":"569_CR108","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1253\/circj.CJ-19-0342","volume":"83","author":"H Tsutsui","year":"2019","unstructured":"Tsutsui H, Isobe M, Ito H, Ito H, Okumura K, Ono M, et al. JCS 2017\/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure\u2014digest version. Circ J. 2019;83:2084\u2013184.","journal-title":"Circ J"},{"key":"569_CR109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1258\/000456304322880069","volume":"41","author":"K Hira","year":"2004","unstructured":"Hira K, Aoki N, Fukui T. Pseudohyperkalaemia at commercial laboratories in Japan: a questionnaire survey. Ann Clin Biochem. 2004;41:155\u20136.","journal-title":"Ann Clin Biochem"},{"key":"569_CR110","doi-asserted-by":"crossref","first-page":"255","DOI":"10.4103\/1947-2714.110426","volume":"5","author":"JR Asirvatham","year":"2013","unstructured":"Asirvatham JR, Moses V, Bjornson L. Errors in potassium measurement: a laboratory perspective for the clinician. N Am J Med Sci. 2013;5:255\u20139.","journal-title":"N Am J Med Sci"},{"key":"569_CR111","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1136\/bmj.330.7497.949","volume":"330","author":"A Ismail","year":"2005","unstructured":"Ismail A, Shingler W, Seneviratne J, Burrows G. In vitro and in vivo haemolysis and potassium measurement. BMJ. 2005;330:949.","journal-title":"BMJ"},{"key":"569_CR112","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","volume":"13","author":"M Epstein","year":"2011","unstructured":"Epstein M, Calhoun DA. Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics. J Clin Hypertens (Greenwich). 2011;13:644\u20138.","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"569_CR113","doi-asserted-by":"publisher","first-page":"261","DOI":"10.3390\/nu10030261","volume":"10","author":"A Cupisti","year":"2018","unstructured":"Cupisti A, Kovesdy CP, D\u2019Alessandro C, Kalantar-Zadeh K. Dietary approach to recurrent or chronic hyperkalaemia in patients with decreased kidney function. Nutrients. 2018;10:261. https:\/\/doi.org\/10.3390\/nu10030261.","journal-title":"Nutrients"},{"key":"569_CR114","first-page":"553","volume":"56","author":"The Japanese Society of Nephrology.","year":"2014","unstructured":"The Japanese Society of Nephrology. Dietary recommendations for chronic kidney disease. Jpn J Nephrol. 2014;56:553\u201399. https:\/\/cdn.jsn.or.jp\/guideline\/pdf\/CKD-Dietaryrecommendations2014.pdf.","journal-title":"Jpn J Nephrol"},{"key":"569_CR115","unstructured":"National Kidney Foundation. Clinical practice guideline for nutrition in chronic kidney disease: 2019 update. National Kidney Foundation. 2019. https:\/\/www.kidney.org\/sites\/default\/files\/Nutrition_GL%2BSubmission_101719_Public_Review_Copy.pdf."},{"key":"569_CR116","unstructured":"Ministry of Education, Culture, Sports, Science and Technology - Japan. Standards tables of food composition in Japan. 7th edition. In: Ministry of Education, Culture, Sports, Science and Technology\u2014Japan. Tokyo; 2015. https:\/\/www.mext.go.jp\/component\/english\/__icsFiles\/afieldfile\/2017\/12\/25\/1374049_1r12_1.xlsx."},{"key":"569_CR117","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3389\/fped.2018.00161","volume":"6","author":"FM Iorember","year":"2018","unstructured":"Iorember FM. Malnutrition in chronic kidney disease. Front Pediatr. 2018;6:161.","journal-title":"Front Pediatr"},{"key":"569_CR118","unstructured":"Lewis JL. Hyperkalemia. 2020. https:\/\/www.msdmanuals.com\/professional\/endocrine-and-metabolic-disorders\/electrolyte-disorders\/hyperkalemia. Accessed 27 Oct 2020."},{"key":"569_CR119","first-page":"s307","volume":"21","author":"JD Dunn","year":"2015","unstructured":"Dunn JD, Benton WW, Orozco-Torrentera E, Adamson RT. The burden of hyperkalemia in patients with cardiovascular and renal disease. Am J Manag Care. 2015;21:s307\u201315.","journal-title":"Am J Manag Care"},{"key":"569_CR120","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.phrs.2016.09.039","volume":"113","author":"P Rossignol","year":"2016","unstructured":"Rossignol P, Legrand M, Kosiborod M, Hollenberg SM, Peacock WF, Emmett M, et al. Emergency management of severe hyperkalemia: guideline for best practice and opportunities for the future. Pharm Res. 2016;113:585\u201391.","journal-title":"Pharm Res"},{"key":"569_CR121","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/01.HYP.0000067463.13172.EA","volume":"41","author":"WB White","year":"2003","unstructured":"White WB, Duprez D, St Hillaire R, Krause S, Roniker B, Kuse-Hamilton J, et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension. 2003;41:1021\u20136.","journal-title":"Hypertension"},{"key":"569_CR122","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1161\/01.HYP.0000025146.19104.FE","volume":"40","author":"H Krum","year":"2002","unstructured":"Krum H, Nolly H, Workman D, He W, Roniker B, Krause S, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40:117\u201323.","journal-title":"Hypertension"},{"key":"569_CR123","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","volume":"7","author":"P Rossignol","year":"2014","unstructured":"Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, et al. Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail. 2014;7:51\u20138.","journal-title":"Circ Heart Fail"},{"key":"569_CR124","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1253\/circj.CJ-17-0323","volume":"82","author":"H Tsutsui","year":"2017","unstructured":"Tsutsui H, Ito H, Kitakaze M, Komuro I, Murohara T, Izumi T, et al. Double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of eplerenone in Japanese patients with chronic heart failure (J-EMPHASIS-HF). Circ J. 2017;82:148\u201358.","journal-title":"Circ J"},{"key":"569_CR125","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1111\/j.1365-2125.2011.04102.x","volume":"73","author":"NC Edwards","year":"2012","unstructured":"Edwards NC, Steeds RP, Chue CD, Stewart PM, Ferro CJ, Townend JN. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease. Br J Clin Pharm. 2012;73:447\u201354.","journal-title":"Br J Clin Pharm"},{"key":"569_CR126","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.2215\/CJN.14751218","volume":"14","author":"S Ito","year":"2019","unstructured":"Ito S, Shikata K, Nangaku M, Okuda Y, Sawanobori T. Efficacy and safety of esaxerenone (CS-3150) for the treatment of type 2 diabetes with microalbuminuria: a randomized, double-blind, placebo-controlled, phase II trial. Clin J Am Soc Nephrol. 2019;14:1161\u201372.","journal-title":"Clin J Am Soc Nephrol"},{"key":"569_CR127","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s12325-019-01121-2","volume":"37","author":"A Kurata","year":"2020","unstructured":"Kurata A, Yoshida T, Inoue M, Ishizuka T, Nakatsu T, Shimizu T, et al. Pharmacokinetics and safety of single-dose esaxerenone in Japanese subjects with mild to moderate hepatic impairment. Adv Ther. 2020;37:253\u201364.","journal-title":"Adv Ther"},{"key":"569_CR128","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1161\/01.CIR.0000071081.35693.9A","volume":"107","author":"NJ Brown","year":"2003","unstructured":"Brown NJ. Eplerenone: cardiovascular protection. Circulation. 2003;107:2512\u20138.","journal-title":"Circulation"},{"key":"569_CR129","first-page":"M","volume":"1","author":"M Fukae","year":"2019","unstructured":"Fukae M, Jamsen K, Shimizu T, Yoshimura M, Yin O, Kastrissios H, et al. Exposure-response analyses for efficacy and safety of esaxerenone, a novel nonsteroidal mineralocorticoid receptor blocker. ACoP10, Orlando, FL. 2019;1:M\u2013014. https:\/\/www.go-acop.org\/assets\/ACoP10\/documents\/ACoP10%20Combined%20Abstracts_2019.pdf.","journal-title":"ACoP10, Orlando, FL"},{"key":"569_CR130","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1210\/jc.2003-032149","volume":"89","author":"DG Levy","year":"2004","unstructured":"Levy DG, Rocha R, Funder JW. Distinguishing the antihypertensive and electrolyte effects of eplerenone. J Clin Endocrinol Metab. 2004;89:2736\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"569_CR131","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/s41371-019-0207-x","volume":"33","author":"S Ito","year":"2019","unstructured":"Ito S, Itoh H, Rakugi H, Okuda Y, Yamakawa S. Efficacy and safety of esaxerenone (CS-3150) for the treatment of essential hypertension: a phase 2 randomized, placebo-controlled, double-blind study. J Hum Hypertens. 2019;33:542\u201351.","journal-title":"J Hum Hypertens"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00569-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00569-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-020-00569-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:22:46Z","timestamp":1684617766000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-020-00569-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11,20]]},"references-count":131,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["569"],"URL":"https:\/\/doi.org\/10.1038\/s41440-020-00569-y","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11,20]]},"assertion":[{"value":"11 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 November 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"HR declares that he has no conflicts of interest. SY and KS are employees of Daiichi Sankyo Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}